Abstract In 2013, the European Heart Rhythm Association (EHRA) published a Practical
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …